Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. ProMIS Neurosciences, Inc.
  6. Company
    PMN   CA74346M1095

PROMIS NEUROSCIENCES, INC.

(PMN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
Business Summary
Logo ProMIS Neurosciences, Inc.
ProMIS Neurosciences Inc, formerly Amorfix Life Sciences Ltd, is a Canada-based development-stage biotech company. The Company discovers and develops precision therapeutics with companion diagnostics for early detection and treatment of neurodegenerative diseases, in particular Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). The assays are developed using its technologies, Epitope Protection and AMFIA. It is developing therapies targeting misfolded, neurotoxic forms of Amyloid beta in AD and superoxide dismutase 1 (SOD1) in ALS. The Company focuses to use its platform to discover further targets for precision medicine solutions through identification of target epitopes on other misfolded strains of Amyloid beta. The Company focuses to evaluate targets on misfolded strains of tau, another protein implicated in neurodegenerative diseases, including Alzheimer's. The Company has not generated any product revenues.
Sales per Business
20192020Delta
CAD (in Million)%CAD (in Million)%
Precision Medicine Solutions0.001100%0.002100% +48.67%
Sales per region
20192020Delta
CAD (in Million)%CAD (in Million)%
Canada0.001100%0.002100% +48.67%
Managers
NameAgeSinceTitle
Elliot Goldstein, Dr.692015President, Chief Executive Officer & Director
Daniel E. Geffken632017Chief Financial Officer
Neil R. Cashman, Dr.-2015Director & Chief Scientific Officer
William W. Wyman822015Independent Director
Patrick D. Kirwin-2015Independent Director
Richard J. Gregory, Dr.622016Independent Director
Johanne Kaplan, Dr.-2016Chief Development Officer
Ernest D. Bush, Dr.-2018Head-Pharmacology & Toxicology
Russell Blacher-2018Head-Manufacturing
David Wishart, Dr.-2021Chief Physics Officer
Members of the board
NameAgeSinceTitle
Eugene Williams602015Executive Chairman
Neil R. Cashman, Dr.-2015Director & Chief Scientific Officer
William W. Wyman822015Independent Director
Elliot Goldstein, Dr.692015President, Chief Executive Officer & Director
Patrick D. Kirwin-2015Independent Director
Richard J. Gregory, Dr.622016Independent Director
Neil K. Warma572021Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 350,950,341 284,839,872 81.2% 0 0.0% 81.2%
Shareholders
NameEquities%
Eugene Williams 8,003,816 2.62%
Elliot Goldstein 7,407,899 2.42%
Neil R. Cashman 6,030,644 1.97%
William W. Wyman 3,776,249 1.23%
Patrick D. Kirwin 3,299,750 1.08%
Boston Private Wealth LLC 189,710 0.062%
F.L. Putnam Investment Management Co. 189,710 0.062%
J. M. Forbes & Co. LLP 73,500 0.024%
David Wendell Associates, Inc. 60,000 0.020%
Arrow Capital Management, Inc. 50,000 0.016%
Company contact information
ProMIS Neurosciences, Inc.
1920 Yonge Street
Suite 200
Toronto, ON M4S 3E2

Phone : +1.416.847.6898
Fax : +1.416.847.6899
Web : http://www.promisneurosciences.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
PROMIS NEUROSCIENCES, INC.115.00%53
GILEAD SCIENCES, INC.14.33%83 541
WUXI APPTEC CO., LTD.24.70%63 775
REGENERON PHARMACEUTICALS11.35%55 705
BIONTECH SE160.57%51 304
VERTEX PHARMACEUTICALS-20.52%48 628
BEIGENE, LTD.24.54%29 784
GENMAB A/S10.52%28 359
ARGENX SE10.41%16 252
HUALAN BIOLOGICAL ENGINEERING INC.-14.44%10 217
NEUROCRINE BIOSCIENCES, INC.4.87%9 504
DENALI THERAPEUTICS INC.-11.97%8 936
ARROWHEAD PHARMACEUTICALS, INC.11.61%8 914
MIRATI THERAPEUTICS, INC.-24.17%8 568
REMEGEN CO., LTD.34.63%8 070
ACCELERON PHARMA INC.0.23%7 784
ASCENDIS PHARMA A/S-15.49%7 587
FATE THERAPEUTICS, INC.-11.77%7 544
EXELIXIS, INC.11.66%7 023
GW PHARMACEUTICALS PLC89.72%6 907
AKESO, INC.62.63%6 504